Pentoxifylline May Aid Diabetic Kidney Disease Markers
A new review suggests the drug helps kidney markers in adults with diabetes, but more trial data is needed.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Should medical researchers prioritize repurposing older, inexpensive generic drugs to treat chronic kidney disease?
A new systematic review and meta-analysis of 34 studies indicates that the drug pentoxifylline may reduce albuminuria and improve GFR in patients with diabetic kidney disease. Experts caution that more data is needed to confirm if the medication ultimately prevents kidney failure or death.
Why it matters
While current results show promising markers for kidney health, most prior research predates modern treatments like SGLT2 inhibitors and GLP-1 receptor agonists. Determining whether this older drug provides clinical benefit in the context of contemporary care is critical for future treatment decisions.
This meta-analysis of 34 studies found a 31% reduction in albuminuria and an average GFR increase of 4.49 mL/min/1.73 m² with pentoxifylline. However, only 3% of the evidence required to assess long-term impacts like kidney failure or death has accrued.
The players
ASN Kidney Week 2026
An annual professional gathering of nephrologists and researchers dedicated to clinical and basic kidney science.
VA PTXRx trial
A large-scale, randomized, placebo-controlled study involving 2376 patients testing pentoxifylline for kidney disease outcomes.
The details
Pentoxifylline is being investigated for its potential to improve kidney function in diabetic patients. The study noted that patients taking the medication experienced a three-fold increase in gastrointestinal adverse events compared to those in control groups. While serious adverse events did not increase, researchers emphasize that the trial results currently focus on biomarkers rather than conclusive clinical outcomes.
Timeline
Most studies reviewed occurred before 2019, prior to the adoption of modern standard medications.
The systematic database search for randomized trials concluded in June 2026.
Findings were presented at ASN Kidney Week 2026 on October 21-25, 2026.
The ongoing VA PTXRx trial expects to report final results in 2027.
Health Landscape
This research sits within the broader investigation of the VA PTXRx trial, which is evaluating long-term outcomes for patients with diabetic kidney disease. It updates the clinical evidence base for pentoxifylline as clinicians continue to refine care models for diabetic complications.
If you have diabetic kidney disease, this data provides a look at an ongoing area of research rather than an immediate change to standard care. These findings are worth discussing with your doctor to understand how your current treatment plan aligns with the latest clinical developments.
The takeaway
While pentoxifylline shows potential for improving short-term markers like albuminuria, its long-term benefits for kidney failure are not yet proven. Keep tracking your kidney function tests and discuss any new study findings with your nephrologist before considering changes to your care plan.
What happens next
The VA PTXRx trial, which is currently evaluating 2376 patients, is expected to provide definitive data on kidney failure and mortality in 2027.
Further reading
For more on evolving standards of care, visit the Diabetes section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical researchers prioritize repurposing older, inexpensive generic drugs to treat chronic kidney disease?
